Ionis Pharmaceuticals’ $632.5 Million Convertible Senior Notes Offering

Davis Polk advised the representatives of the several purchasers in offering.

Ionis Pharmaceuticals, Inc. executed its offering of an aggregate principal amount of $632.5 million of its 0% convertible senior notes due 2026, which included $82.5 million aggregate principal amount of notes sold pursuant to the purchasers’ fully exercised option. 

Ionis is a leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology.

The Davis Polk corporate team advising Goldman Sachs & Co. LLC and Stifel, Nicolaus & Company, Incorporated, as representatives of the several purchasers, included partner Alan F. Denenberg (Picture) and associates Dongbiao Shen and Paula Gergen. The equity derivatives team included partner Ray Ibrahim, counsel Katharine O’Banion and associate Danielle Forni. The tax team included partner Michael Farber and associate Ben Levenback. The intellectual property and technology transactions team included partner David R. Bauer and associate Jay Frankel. 

Involved fees earner: David Bauer – Davis Polk & Wardwell; Alan Denenberg – Davis Polk & Wardwell; Michael Farber – Davis Polk & Wardwell; Danielle Forni – Davis Polk & Wardwell; Jay Frankel – Davis Polk & Wardwell; Paula Gergen – Davis Polk & Wardwell; Ray Ibrahim – Davis Polk & Wardwell; Ben Levenback – Davis Polk & Wardwell; Katharine O’Banion – Davis Polk & Wardwell; Dongbiao Shen – Davis Polk & Wardwell;

Law Firms: Davis Polk & Wardwell;

Clients: Goldman Sachs & Co.; Stifel, Nicolaus & Company, Incorporated;

Print Friendly, PDF & Email
Martina Bellini

Author: Martina Bellini